Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma

Journal of Immunology

Volumn 183, Issue 2, 2009, Pages 832-840

  Condomines, Maud ^a,b,c   Hose, Dirk ^d,e   Rème, Thierry ^a,b   Requirand, Guilhem ^a   Hundemer, Michael ^d,e   Schoenhals, Matthieu ^b,c   Goldschmidt, Hartmut ^d,e   Klein, Bernard ^a,b,c  

^a HÔPITAL SAINT ELOI   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e Nationales Centrum fur Tumorerkrankungen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; HG U133 PROTEIN; MESSENGER RNA; PROTEIN; TEX14 PROTEIN; UNCLASSIFIED DRUG; RNA; TUMOR ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; GENE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SAMPLE; TESTIS; VALIDATION STUDY; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; RNA; TESTIS; TISSUE DISTRIBUTION;

EID: 70249139924     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803298     Document Type: Article

References (76)

1. Scanlan, M. J., A. J. Simpson, and L. J. Old. 2004. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4: 1.
2. Wang, Z., Y. Zhang, A. Mandal, J. Zhang, F. J. Giles, J. C. Herr, and S. H. Lim. 2004. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin. Cancer Res. 10: 6544-6550.
3. Monji, M., T. Nakatsura, S. Senju, Y. Yoshitake, M. Sawatsubashi, M. Shinohara, T. Kageshita, T. Ono, A. Inokuchi, and Y. Nishimura. 2004. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin. Cancer Res. 10: 6047-6057.
4. Chen, Y. T., M. J. Scanlan, C. A. Venditti, R. Chua, G. Theiler, B. J. Stevenson, C. Iseli, A. O. Gure, T. Vasicek, R. L. Strausberg, et al. 2005. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc. Natl. Acad. Sci. USA 102: 7940-7945. (Pubitemid 40781042)
5. van Baren, N., M. C. Bonnet, B. Dreno, A. Khammari, T. Dorval, S. Piperno-Neumann, D. Lienard, D. Speiser, M. Marchand, V. G. Brichard, et al. 2005. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23: 9008-9021.
6. Jager, E., J. Karbach, S. Gnjatic, A. Neumann, A. Bender, D. Valmori, M. Ayyoub, E. Ritter, G. Ritter, D. Jager, et al. 2006. Recombinant vaccinia/ fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA 103: 14453-14458.
7. Odunsi, K., F. Qian, J. Matsuzaki, P. Mhawech-Fauceglia, C. Andrews, E. W. Hoffman, L. Pan, G. Ritter, J. Villella, B. Thomas, et al. 2007. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. USA 104: 12837-12842.
8. Pellat-Deceunynck, C., M. P. Mellerin, N. Labarriere, G. Jego, A. Moreau-Aubry, J. L. Harousseau, F. Jotereau, and R. Bataille. 2000. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur. J. Immunol. 30: 803-809. (Pubitemid 30216252)
9. Tarte, K., F. Zhan, J. De Vos, B. Klein, and J. Shaughnessy, Jr. 2003. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 102: 592-600.
10. Dhodapkar, M. V., K. Osman, J. Teruya-Feldstein, D. Filippa, C. V. Hedvat, K. Iversen, D. Kolb, M. D. Geller, H. Hassoun, T. Kewalramani, et al. 2003. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 3: 9.
11. Condomines, M., D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J. F. Schved, et al. 2007. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J. Immunol. 178: 3307-3315.
12. Jungbluth, A. A., S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y. T. Chen, N. Bhardwaj, S. Chen-Kiang, L. J. Old, and H. J. Cho. 2005. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106: 167-174.
13. van Rhee, F., S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, and G. Tricot. 2005. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105: 3939-3944.
14. + T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106: 4217-4224.
15. Atanackovic, D., J. Arfsten, Y. Cao, S. Gnjatic, F. Schnieders, K. Bartels, G. Schilling, C. Faltz, C. Wolschke, J. Dierlamm, et al. 2007. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109: 1103-1112.
16. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
17. Weinschenk, T., C. Gouttefangeas, M. Schirle, F. Obermayr, S. Walter, O. Schoor, R. Kurek, W. Loeser, K. H. Bichler, D. Wernet, et al. 2002. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62: 5818-5827. (Pubitemid 35204741)
18. Cavallo, F., A. Astolfi, M. Iezzi, F. Cordero, P. L. Lollini, G. Forni, and R. Calogero. 2005. An integrated approach of immunogenomics and bioinformatics to identify new tumor associated antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics. 6(Suppl. 4): S7.
19. Segal, N. H., N. E. Blachere, J. A. Guevara-Patino, H. F. Gallardo, H. Y. Shiu, A. Viale, C. R. Antonescu, J. D. Wolchok, and A. N. Houghton. 2005. Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun. 5: 2.
20. Zhang, X. G., J. P. Gaillard, N. Robillard, Z. Y. Lu, Z. J. Gu, M. Jourdan, J. M. Boiron, R. Bataille, and B. Klein. 1994. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83: 3654-3663.
21. Rebouissou, C., J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J. F. Rossi, J. Brochier, and B. Klein. 1998. A gp130 interleukin-6 transducerdependent SCID model of human multiple myeloma. Blood 91: 4727-4737. (Pubitemid 28270323)
22. Tarte, K., X. G. Zhang, E. Legouffe, C. Hertog, M. Mehtali, J. F. Rossi, and B. Klein. 1999. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J. Immunol. 163: 514-524. (Pubitemid 29295881)
23. Gu, Z. J., J. De Vos, C. Rebouissou, M. Jourdan, X. G. Zhang, J. F. Rossi, J. Wijdenes, and B. Klein. 2000. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 14: 188-197.
24. De Vos, J., T. Thykjaer, K. Tarte, M. Ensslen, P. Raynaud, G. Requirand, F. Pellet, V. Pantesco, T. Reme, M. Jourdan, et al. 2002. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 21: 6848-6857.
25. Assou, S., T. Le Carrour, S. Tondeur, S. Strom, A. Gabelle, S. Marty, L. Nadal, V. Pantesco, T. Reme, J. P. Hugnot, et al. 2007. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells 25: 961-973.
26. Su, A. I., T. Wiltshire, S. Batalov, H. Lapp, K. A. Ching, D. Block, J. Zhang, R. Soden, M. Hayakawa, G. Kreiman, et al. 2004. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA 101: 6062-6067.
27. Rhodes, D. R., J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, and A. M. Chinnaiyan. 2004. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. USA 101: 9309-9314.
28. Zhan, F., Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al. 2006. The molecular classification of multiple myeloma. Blood 108: 2020-2028.
29. Greenbaum, M. P., W. Yan, M. H. Wu, Y. N. Lin, J. E. Agno, M. Sharma, R. E. Braun, A. Rajkovic, and M. M. Matzuk. 2006. TEX14 is essential for intercellular bridges and fertility in male mice. Proc. Natl. Acad. Sci. USA 103: 4982-4987.
30. Abe, K., O. Chisaka, F. Van Roy, and M. Takeichi. 2004. Stability of dendritic spines and synaptic contacts is controlled by αN-catenin. Nat. Neurosci. 7: 357-363.
31. Ambasudhan, R., X. Wang, M. M. Jablonski, D. A. Thompson, P. S. Lagali, P. W. Wong, P. A. Sieving, and R. Ayyagari. 2004. Atrophic macular degeneration mutations in ELOVL4 result in the intracellular misrouting of the protein. Genomics 83: 615-625.
32. Zhang, K., M. Kniazeva, M. Han, W. Li, Z. Yu, Z. Yang, Y. Li, M. L. Metzker, R. Allikmets, D. J. Zack, et al. 2001. A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat. Genet. 27: 89-93.
33. Suzu, S., Y. Hayashi, T. Harumi, K. Nomaguchi, M. Yamada, H. Hayasawa, and K. Motoyoshi. 2002. Molecular cloning of a novel immunoglobulin superfamily gene preferentially expressed by brain and testis. Biochem. Biophys. Res. Commun. 296: 1215-1221.
34. Katoh, M. 2003. IGSF11 gene, frequently up-regulated in intestinal-type gastric cancer, encodes adhesion molecule homologous to CXADR, FLJ22415 and ESAM. Int. J. Oncol. 23: 525-531.
35. Watanabe, T., T. Suda, T. Tsunoda, N. Uchida, K. Ura, T. Kato, S. Hasegawa, S. Satoh, S. Ohgi, H. Tahara, Y. Furukawa, and Y. Nakamura. 2005. Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci. 96: 498-506.
36. Horie, M., Y. Mitsumoto, H. Kyushiki, N. Kanemoto, A. Watanabe, Y. Taniguchi, N. Nishino, T. Okamoto, M. Kondo, T. Mori, et al. 2000. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephalic neurons. Genomics 67: 146-152.
37. Gery, S., D. Yin, D. Xie, K. L. Black, and H. P. Koeffler. 2003. TMEFF1 and brain tumors. Oncogene 22: 2723-2727.
38. Uchida, T., K. Wada, T. Akamatsu, M. Yonezawa, H. Noguchi, A. Mizoguchi, M. Kasuga, and C. Sakamoto. 1999. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem. Biophys. Res. Commun. 266: 593-602.
39. Mahtouk, K., F. W. Cremer, T. Reme, M. Jourdan, M. Baudard, J. Moreaux, G. Requirand, G. Fiol, J. De Vos, M. Moos, et al. 2006. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 25: 7180-7191.
40. Young, J., K. G. Biden, L. A. Simms, P. Huggard, R. Karamatic, H. J. Eyre, G. R. Sutherland, N. Herath, M. Barker, G. J. Anderson, et al. 2001. HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc. Natl. Acad. Sci. USA 98: 265-270.
41. Gery, S., C. L. Sawyers, D. B. Agus, J. W. Said, and H. P. Koeffler. 2002. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 21: 4739-4746.
42. Fodero-Tavoletti, M. T., M. P. Hardy, B. Cornell, F. Katsis, C. M. Sadek, C. A. Mitchell, B. E. Kemp, and T. Tiganis. 2005. Protein tyrosine phosphatase hPTPN20a is targeted to sites of actin polymerization. Biochem. J. 389: 343-354.
43. Gecz, J., D. Cloosterman, and M. Partington. 2006. ARX: a gene for all seasons. Curr. Opin. Genet. Dev. 16: 308-316.
44. Stromme, P., M. E. Mangelsdorf, M. A. Shaw, K. M. Lower, S. M. Lewis, H. Bruyere, V. Lutcherath, A. K. Gedeon, R. H. Wallace, I. E. Scheffer, et al. 2002. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat. Genet. 30: 441-445.
45. Kitamura, K., M. Yanazawa, N. Sugiyama, H. Miura, A. Iizuka-Kogo, M. Kusaka, K. Omichi, R. Suzuki, Y. Kato-Fukui, K. Kamiirisa, et al. 2002. Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. Nat. Genet. 32: 359-369.
46. Tarnasky, H., D. Gill, S. Murthy, X. Shao, D. J. Demetrick, and F. A. van der Hoorn. 1998. A novel testis-specific gene, SPAG4, whose product interacts specifically with outer dense fiber protein ODF27, maps to human chromosome 20q11.2. Cytogenet. Cell Genet. 81: 65-67. (Pubitemid 28380102)
47. Kennedy, C., K. Sebire, D. M. de Kretser, and M. K. O'Bryan. 2004. Human sperm associated antigen 4 (SPAG4) is a potential cancer marker. Cell Tissue Res. 315: 279-283.
48. Galea, I., I. Bechmann, and V. H. Perry. 2007. What is immune privilege (not)? Trends Immunol. 28: 12-18.
49. Starr, T. K., S. C. Jameson, and K. A. Hogquist. 2003. Positive and negative selection of T cells. Annu. Rev. Immunol. 21: 139-176.
50. Palmer, E. 2003. Negative selection: clearing out the bad apples from the T-cell repertoire. Nat. Rev. Immunol. 3: 383-391.
51. Zehn, D., and M. J. Bevan. 2006. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25: 261-270.
52. Belle, S., F. Han, M. Condomines, O. Christensen, M. Witzens-Harig, B. Kasper, C. Kleist, P. Terness, M. Moos, F. Cremer, et al. 2008. Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma. Eur. J. Haematol. 81: 26-35.
53. Hundemer, M., S. Schmidt, M. Condomines, A. Lupu, D. Hose, M. Moos, F. Cremer, C. Kleist, P. Terness, S. Belle, et al. 2006. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp. Hematol. 34: 486-496.
54. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
55. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152: 163-175. (Pubitemid 24974579)
56. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
57. Bredel, M., C. Bredel, D. Juric, G. R. Harsh, H. Vogel, L. D. Recht, and B. I. Sikic. 2005. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 65: 8679-8689.
58. Ginos, M. A., G. P. Page, B. S. Michalowicz, K. J. Patel, S. E. Volker, S. E. Pambuccian, F. G. Ondrey, G. L. Adams, and P. M. Gaffney. 2004. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 64: 55-63.
59. Talantov, D., A. Mazumder, J. X. Yu, T. Briggs, Y. Jiang, J. Backus, D. Atkins, and Y. Wang. 2005. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11: 7234-7242.
60. Zhan, F., J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng, E. Tian, R. Sanderson, Y. Yang, C. Wilson, M. Zangari, et al. 2002. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745-1757.
61. Lancaster, J. M., H. K. Dressman, R. S. Whitaker, L. Havrilesky, J. Gray, J. R. Marks, J. R. Nevins, and A. Berchuck. 2004. Gene expression patterns that characterize advanced stage serous ovarian cancers. J. Soc. Gynecol. Invest. 11: 51-59.
62. Chen, X., S. T. Cheung, S. So, S. T. Fan, C. Barry, J. Higgins, K. M. Lai, J. Ji, S. Dudoit, I. O. Ng, et al. 2002. Gene expression patterns in human liver cancers. Mol. Biol. Cell 13: 1929-1939.
63. Richardson, A. L., Z. C. Wang, A. De Nicolo, X. Lu, M. Brown, A. Miron, X. Liao, J. D. Iglehart, D. M. Livingston, and S. Ganesan. 2006. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132.
64. Dyrskjot, L., M. Kruhoffer, T. Thykjaer, N. Marcussen, J. L. Jensen, K. Moller, and T. F. Orntoft. 2004. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64: 4040-4048.
65. Andersson, A., C. Ritz, D. Lindgren, P. Eden, C. Lassen, J. Heldrup, T. Olofsson, J. Rade, M. Fontes, A. Porwit-Macdonald, et al. 2007. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 21: 1198-1203.
66. Korkola, J. E., J. Houldsworth, R. S. Chadalavada, A. B. Olshen, D. Dobrzynski, V. E. Reuter, G. J. Bosl, and R. S. Chaganti. 2006. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 66: 820-827.
67. Sun, L., A. M. Hui, Q. Su, A. Vortmeyer, Y. Kotliarov, S. Pastorino, A. Passaniti, J. Menon, J. Walling, R. Bailey, et al. 2006. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9: 287-300.
68. Vanaja, D. K., J. C. Cheville, S. J. Iturria, and C. Y. Young. 2003. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63: 3877-3882.
69. Tomlins, S. A., R. Mehra, D. R. Rhodes, X. Cao, L. Wang, S. M. Dhanasekaran, S. Kalyana-Sundaram, J. T. Wei, M. A. Rubin, K. J. Pienta, R. B. Shah, and A. M. Chinnaiyan. 2007. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39: 41-51.
70. Buchholz, M., M. Braun, A. Heidenblut, H. A. Kestler, G. Kloppel, W. Schmiegel, S. A. Hahn, J. Luttges, and T. M. Gress. 2005. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24: 6626-6636.
71. Zou, T. T., F. M. Selaru, Y. Xu, V. Shustova, J. Yin, Y. Mori, D. Shibata, F. Sato, S. Wang, A. Olaru, E. Deacu, T. C. Liu, J. M. Abraham, and S. J. Meltzer. 2002. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21: 4855-4862.
72. Garber, M. E., O. G. Troyanskaya, K. Schluens, S. Petersen, Z. Thaesler, M. Pacyna-Gengelbach, M. van de Rijn, G. D. Rosen, C. M. Perou, R. I. Whyte, et al. 2001. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 98: 13784-13789.
73. Graudens, E., V. Boulanger, C. Mollard, R. Mariage-Samson, X. Barlet, G. Gremy, C. Couillault, M. Lajemi, D. Piatier-Tonneau, P. Zaborski, et al. 2006. Deciphering cellular states of innate tumor drug responses. Genome Biol. 7: R19.
74. Sanchez-Carbayo, M., N. D. Socci, J. Lozano, F. Saint, and C. Cordon-Cardo. 2006. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24: 778-789.
75. Lu, K. H., A. P. Patterson, L. Wang, R. T. Marquez, E. N. Atkinson, K. A. Baggerly, L. R. Ramoth, D. G. Rosen, J. Liu, I. Hellstrom, et al. 2004. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10: 3291-3300.
76. Gumz, M. L., H. Zou, P. A. Kreinest, A. C. Childs, L. S. Belmonte, S. N. LeGrand, K. J. Wu, B. A. Luxon, M. Sinha, A. S. Parker, et al. 2007. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin. Cancer Res. 13: 4740-4749.